If-ingibitory - novyy klass lekarstvennykh preparatov dlya lecheniya stabil'noy stenokardii


Cite item

Full Text

Abstract

Ионный f-канал синусового узла регулирует и контролирует ЧСС. В последние годы создан новый класс препаратов - If-ингибиторы, единственным представителем является ивабрадин. В ряде крупных исследований показана его антиангинальная активность при стабильной стенокардии напряжения при минимуме побочных эффектов и высокой сердечно-сосудистой безопасности. В настоящее время ивабрадин применяется для лечения стабильной стенокардии при непереносимости или противопоказаниях к применению b-блокаторов. Кроме того, на наш взгляд, препарат может быть перспективным в лечении других заболеваний сердечно-сосудистой системы, таких как хроническая сердечная недостаточность, инфаркт миокарда и т.д. (особенно при наличии непереносимости или противопоказаний к назначениюb-блокаторов). Литература

About the authors

N. Sh Zagidullin

Башкирский государственный медицинский университет, Уфа

References

  1. Hjalmarson A, Gilpin E.A, Kjekshus J et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53.
  2. Jouven X, Empana J-P, Schwartz P. Heart Rate Profile during Exercise e as a Predictor of Sudden Cardiac Death. N Eng J Med 2005; 352: 1951-8.
  3. Kannel W.B, Kannel C, Paffangarger R.S.Jr et al. Heart rate and cardiovascular mortality: the Framingem study. An Heart J 1987; 113: 1489-94.
  4. Kristal-Boneh E, Silber H, Harari G et al. The association of resting heart rate with cardiovascular, cancer and all - cause mortality. Eight year follow - up 0f 3257 male Israel employees. Eur Heart J 2000; 21: 115-24.
  5. Gilman M. Kannel W, Belanger A, D'Agostino R. Influence of heart rate on mortality among persons with hypertension The Framingham study. Am H J 1993; 125: 1148-54.
  6. Gillum R, Makus D, Feldman J. Pulse rate, coronary heart disease and death: The NHANES I epidemiological follow - up study. Am Heart J 1991; 121: 172-7.
  7. Shell W, Sobel B. Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol 1973; 31: 474-9.
  8. Perski A, Hamsten A, Lindvall K, Theorel T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988; 116: 1369-73.
  9. Brown H.F, Di Francesco D, Noble S.J. How does adrenaline accelerate the heart? Nature 1979; 280 (5719): 235-6.
  10. Wainger B.J, Degennaro M, Santoro B et al. Molecular mechanism of cAMP modulation of HCN pacemaker channels. Nature 2001; 411: 805-10.
  11. Van Bogaert P, Goethals M. Pharmacological influence of specific bradycardic events on the pacemaker current of ship cardiac Purkihje fibers. A comparison between free different molecules. Eur Heart J 1987; 8 (Suppl. L): 35-2.
  12. Di Francesco D, Camm J.A. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64 (16): 1757-65.
  13. Ivabradine hydrochloride. Drug future 2003; 28 (7): 652-8.
  14. Di Francesco D. Cardiac pacemaker If current and its inhibition by heart rate reducing agents. Current medical research and opinion 2005; 21(7): 1115-22.
  15. Thollon C, Cambarrat C, Vian J et al. Electrophysiological effects of s16257, a novel sino - atrial node modulator, on rabbit and guinea pigs cardiac preparations: comparison with UL-FS 49. Br J Pharmacol 1994; 112: 37-4.
  16. Manz M, Reuter M, Lauck G et al. A Single Intravenous Dose of Ivabradine, a Novel If Inhibitor, Lowers Heart Rate but Does not Depress Left Ventricular Function in Patients with Left Ventricular Dysfunction. Cardiology 2003; 100: 149-55.
  17. Camm J, Lau C-P. Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S16257) in Adult Patients with Normal Baseline Electrophysiology. Drugs 2003; 4 (2): 83-8.
  18. Monnet X, Ghalen B, Colen P et al. Effects of Heart Rate Reduction with Ivabradine on Exercise-Induced Myocardial Ischemia and Stunning. J Phar Exper Ther 2001; 299: 1133-9.
  19. Bois P, Bescond J, Renaudon B et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoartrial node cells. Br J Pharmacol 1996; 118: 1051-7.
  20. Bucchi A, Baruscotti M, Di Francesco D. Current - dependent Block of Sinoartreal Node If Channels by Ivabradine. J Gen Physiol 2002; 120: 1-13.
  21. Vilaine J.P, Bidouard J.P, Leasge L et al. Anti-Ischemic Effects of Ivabradine, a Selective Heart Rate-Reducing Agent, in Exercise-Induced Myocardial Ischemia in Pigs. J Cardiovasc Pharmacol 2003; 42: 688-96.
  22. Simon L, Ghalen B, Puybasset L. Coronary and Hemodynamic Effects of S 16257, a New Bradycardic Agent, in Resting and Exercising Conscious Dogs. J Pharmac Exp Ther 1995; 275 (2): 659-66.
  23. Ragueneau I, Laville C, Jochemsen R et al. Pharmacokinetic - pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998; 64: 192-203.
  24. Borer J, Fox K, Jaillon P. Antianginal and Antiischemic Effects of Ivabradine, an If Inhibitor, in Stable Angina. A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial. Circulation 2003; 107: 817-23.
  25. Mulder P, Barbier S, Chagraou A et al. Long Term Heart Rate Reduction Induced by a Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure. Circulation 2004; 109: 1674-9.
  26. Colin P, Ghaleh B, Monnet X et al. Contributions of haer rate and contractility tomyocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 2003; 284: H676-82.
  27. Ruzyllo W, Ford I.F, Tendera M.T, Fox K.F. Anti - anginal and anti - ischemic effects of the Ша current inhibitor ivabradine compared to amlodipide as monotherapeis in patients with chronic stable angina. Randomised, controlled, double - blind study. Eur Heart 2004; 25 (Suppl.): 138{A878}.
  28. Tardif J.C. Clinical Efficacy of Ivabradine. Heart Drug 2005; 5: 25-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2006 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).